These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 21944287)

  • 21. Development of new fluorescent xanthines as kinase inhibitors.
    Kim D; Jun H; Lee H; Hong SS; Hong S
    Org Lett; 2010 Mar; 12(6):1212-5. PubMed ID: 20184370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological activities of novel hexahydropyrazino[1,2-a]indole derivatives as potent inhibitors of apoptosis (IAP) proteins antagonists with improved membrane permeability across MDR1 expressing cells.
    Shiokawa Z; Hashimoto K; Saito B; Oguro Y; Sumi H; Yabuki M; Yoshimatsu M; Kosugi Y; Debori Y; Morishita N; Dougan DR; Snell GP; Yoshida S; Ishikawa T
    Bioorg Med Chem; 2013 Dec; 21(24):7938-54. PubMed ID: 24169315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of glaucoma.
    Chen HH; Namil A; Severns B; Ward J; Kelly C; Drace C; McLaughlin MA; Yacoub S; Li B; Patil R; Sharif N; Hellberg MR; Rusinko A; Pang IH; Combrink KD
    Bioorg Med Chem Lett; 2014 Apr; 24(8):1875-9. PubMed ID: 24684843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors.
    Chioua M; Samadi A; Soriano E; Lozach O; Meijer L; Marco-Contelles J
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4566-9. PubMed ID: 19615897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis of 2,6-diphenylpyrazine derivatives and their DNA binding and cytotoxic properties.
    Dias N; Jacquemard U; Baldeyrou B; Lansiaux A; Goossens JF; Bailly C; Routier S; Mérour JY
    Eur J Med Chem; 2005 Dec; 40(12):1206-13. PubMed ID: 16153749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors.
    Putey A; Fournet G; Lozach O; Perrin L; Meijer L; Joseph B
    Eur J Med Chem; 2014 Aug; 83():617-29. PubMed ID: 24998602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological evaluation of novel oxophenylarcyriaflavins as potential anticancer agents.
    Bourderioux A; Bénéteau V; Mérour JY; Baldeyrou B; Ballot C; Lansiaux A; Bailly C; Le Guével R; Guillouzo C; Routier S
    Org Biomol Chem; 2008 Jun; 6(12):2108-17. PubMed ID: 18528573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, resolution, and biological evaluation of atropisomeric (aR)- and (aS)-16-methyllamellarins N: unique effects of the axial chirality on the selectivity of protein kinases inhibition.
    Yoshida K; Itoyama R; Yamahira M; Tanaka J; Loaëc N; Lozach O; Durieu E; Fukuda T; Ishibashi F; Meijer L; Iwao M
    J Med Chem; 2013 Sep; 56(18):7289-301. PubMed ID: 23981088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro antiproliferative activities and kinase inhibitory potencies of glycosyl-isoindigo derivatives.
    Sassatelli M; Bouchikhi F; Aboab B; Anizon F; Fabbro D; Prudhomme M; Moreau P
    Anticancer Drugs; 2007 Oct; 18(9):1069-74. PubMed ID: 17704657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
    Charrier JD; Durrant SJ; Golec JM; Kay DP; Knegtel RM; MacCormick S; Mortimore M; O'Donnell ME; Pinder JL; Reaper PM; Rutherford AP; Wang PS; Young SC; Pollard JR
    J Med Chem; 2011 Apr; 54(7):2320-30. PubMed ID: 21413798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells.
    Bouloc N; Large JM; Kosmopoulou M; Sun C; Faisal A; Matteucci M; Reynisson J; Brown N; Atrash B; Blagg J; McDonald E; Linardopoulos S; Bayliss R; Bavetsias V
    Bioorg Med Chem Lett; 2010 Oct; 20(20):5988-93. PubMed ID: 20833547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles.
    Boschelli DH; Wu B; Barrios Sosa AC; Durutlic H; Chen JJ; Wang Y; Golas JM; Lucas J; Boschelli F
    J Med Chem; 2005 Jun; 48(11):3891-902. PubMed ID: 15916442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
    Lee J; Kim H; Yu H; Chung JY; Oh CH; Yoo KH; Sim T; Hah JM
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1573-7. PubMed ID: 20149658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).
    Murphy ST; Alton G; Bailey S; Baxi SM; Burke BJ; Chappie TA; Ermolieff J; Ferre R; Greasley S; Hickey M; Humphrey J; Kablaoui N; Kath J; Kazmirski S; Kraus M; Kupchinsky S; Li J; Lingardo L; Marx MA; Richter D; Tanis SP; Tran K; Vernier W; Xie Z; Yin MJ; Yu XH
    J Med Chem; 2011 Dec; 54(24):8490-500. PubMed ID: 22040023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Syntheses and anti-cancer activities of 2-[1-(indol-3-yl-/pyrimidin-5-yl-/pyridine-2-yl-/quinolin-2-yl)-but-3-enylamino]-2-phenyl-ethanols.
    Singh P; Kaur P; Luxami V; Kaur S; Kumar S
    Bioorg Med Chem; 2007 Mar; 15(6):2386-95. PubMed ID: 17275313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.
    Garamvölgyi R; Dobos J; Sipos A; Boros S; Illyés E; Baska F; Kékesi L; Szabadkai I; Szántai-Kis C; Kéri G; Őrfi L
    Eur J Med Chem; 2016 Jan; 108():623-643. PubMed ID: 26724730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and PKCtheta inhibitory activity of a series of 5-vinyl phenyl sulfonamide-3-pyridinecarbonitriles.
    Shim J; Eid C; Lee J; Liu E; Chaudhary D; Boschelli DH
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6575-7. PubMed ID: 19854645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.
    Reader JC; Matthews TP; Klair S; Cheung KM; Scanlon J; Proisy N; Addison G; Ellard J; Piton N; Taylor S; Cherry M; Fisher M; Boxall K; Burns S; Walton MI; Westwood IM; Hayes A; Eve P; Valenti M; de Haven Brandon A; Box G; van Montfort RL; Williams DH; Aherne GW; Raynaud FI; Eccles SA; Garrett MD; Collins I
    J Med Chem; 2011 Dec; 54(24):8328-42. PubMed ID: 22111927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.